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ABSTRACT: Candida species are the most common fungal pathogens isolated from the oral cavity. Their oral
existence both as a commensal and an opportunist pathogen has intrigued clinicians and scientists for many
decades, and recent investigations have revealed many attributes of this fungus contributing to its pathogenicity.
In addition, the advent of the human immunodeficiency virus infection and AIDS has resulted in a resurgence of
oral Candida infections. Clinicians are witnessing not only classic forms of the diseases but also newer clinical
variants such as erythematous candidosis, rarely described hithertofore. Therefore, this review is an attempt at
detailing the current knowledge on Candida and oral candidoses together with the newer therapeutic regimes
employed in treating these mycoses.
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1. INTRODUCTION
The advent of the human immunodeficiency
virus infection and AIDS has resulted in a resur-
gence of oral Candida infections that are usually
seen in the very young, the very old, and the very
sick. Candida albicans is the most common Can-
dida species isolated from the oral cavity both in
health and disease, while other species such as
C. glabrata, C. tropicalis, and C. guilliermondii
are infrequently but consistently isolated (Sam-
aranayake, 1990a). C. albicans is a dimorphic
fungus existing both in the blastospore phase (syn.
yeast phase, blastoconidial phase) and the hyphal
or mycelial phase. Although these organisms typi-
cally colonize mucocutaneous surfaces, the latter
can be portals of entry into deeper tissues when
host defenses are compromised (Rogers and
Balish, 1980).
An excellent account of systemic candidosis
can be found in monographs by Odds (1988) and
Tumbay et al. (1991), while the subject of oral
candidosis has been addressed recently in detail
by Samaranayake and MacFarlane (1990).
I. TAXONOMY AND TYPING OF
CANDIDA
The genus Candida is a collection of some
150 asporogenous yeast species. Because of their
inability to form a sexual stage, they are most
often classified among the fungi imperfecti in the
class Deuteromycetes (Lodder, 1970). Seven
Candida species are ofmajor medical importance,
and of these C. albicans, C. tropicalis, and
C. glabrata are the most frequently isolated (more
than 80%) from medical specimens. The other
pathogenic Candida species are C. parapsilosis,
C. stellatoidea, C. guilliermnondii, C. krusei, and
C. pseudotropicalis. Candida stellatoidea is dif-
ferentiated from Candida albicans by its inability
to assimilate sucrose. However, the high DNA
homology between the two yeasts led Meyer et al.
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(1984) to classify C. stellatoidea as a sucrose-
negative variant of C. albicans.
Within the class Deuteromycetes, the distin-
guishing feature of the Candida species is their
ability to form pseudohyphae, the only exception
being C. glabrata (Lodder, 1970). A number of
techniques have been used over the years to dif-
ferentiate Candida isolates either belonging to
different species or belonging to the same spe-
cies. These are annotated below.
A. DNA Base Composition
The base composition of nuclear and mito-
chondrial DNA in yeasts is expressed as the mo-
lar percentages of guanine plus cytosine (G+C)
(Kurtzman and Phaff, 1987). The G+C content
among species within a genus often varies within
10%, but differences much above 10% may suggest
that the genus in which the organisms have been
placed is composed of several genera (Olsen, 1990).
B. Typing and Mapping of DNA
DNA typing methods based on digestion and
electrophoresis ofDNA fragments appear to offer
important potential advantages over phenotypic
methods in taxonomy. Such methods provide a
basis for the development of cloned probes for
studies on DNA homology (Scherer and Stevens,
1987; Fox et al., 1989).
C. DNA-DNA Homology
DNA-DNA complimentarity experiments
measure the fidelity of complementary base pair-
ing of denatured DNA strands from test pairs
(Leth and Stenderup, 1969).
D. Ribosomal RNA
Ribosomal RNA (rRNA)-DNA homology
studies have been made with species of relatively
few genera. The data suggest that intrageneric
relationships established with this method are not
usually meaningful, owing to the high degree of
conservation of the DNA sequences coding for
rRNA (Phaff, 1984).
E. Enzymes
The amino acid sequence of enzymes such as
glutamine synthetase and superoxide dismutase
determined with quantitative microcomplement
fixation may help evaluate the relationship be-
tween yeasts (Kurtzman and Phaff, 1987).
Alloenzyme electrophoresis is based on the idea
that genetic diversity develops over time. This
implies that genetically distant organisms show
major differences in protein composition, and that
more closely related organisms show a high de-
gree of similarity in protein composition.
Alloenzyme analysis is even more sensitive for
studying intraspecific variation among yeasts than
DNA-DNA sequence complementarity (Kurtzman
and Phaff, 1987; Odds, 1988).
F. Cellular Protein/polypeptide Profiles
Autoradiographic analysis of (35S) methion-
ine-labeled cellular proteins separated by sodium
dodecyl sulfate-polyacrylamide gel electrophore-
sis shows that different Candida species and other
yeast species produce distinct patterns (Shen et al.,
1988).
G. Killer Systems
Killer toxins of yeast may be useful for differ-
entiating strain types among the pathogenic spe-
cies for surveillance studies (Morace et al., 1983)
and to determine their geographic distribution
(Young, 1987).
H. Carbohydrates
Capsular and cell wall polysaccharides have
been used in taxonomic studies, particularly at the
generic level (Weijman and Rodriguez De
Miranda, 1988). Differentiation between yeasts
has also been made from the absence or presence
of glucuronic acid or D-xylose in the cell walls
(Phaff, 1984).
1. Other Typing Methods
Other typing methods that use less sophisti-
cated technology and commercially available
media include resistogram method, API ZYM,
126
API 20C, and boric acid resistance assay, and
colony morphotyping (Silverman et al., 1990).
III. CANDIDA CARRIAGE IN THE ORAL
CAVITY
A. Prevalence Data
Symptom-free oral carriage of Candida or-
ganisms has been recognized for many years.
Figures obtained on the frequency of yeast car-
riage in the oral cavity are dependent on isolation
techniques and time of sampling (Odds, 1988).
The reported prevalence in clinically normal
mouths of healthy adults ranges from 3 to 48%
(Arendorf and Walker, 1980), and in 45 to 65% of
healthy children (Odds, 1988).
Odds (1988) has analyzed a large number of
papers on oral carriage from the literature (Table
1). From 32 papers on yeast isolation from the
oral cavity in "normals", the median carriage fre-
quency was 34.4% for all yeasts and 17% for
C. albicans alone. In children there was a peak in
carriage between the age of 1 week and 18 months.
C. albicans is the most dominant species, fol-
lowed by C. tropicalis, C. glabrata, C. parapsilosis,
and C. krusei. Other Candida species and genera
TABLE 1
Carriage of Oral Candida
Published carriage frequencies
(%)
Sample details
No. of
papers
Yeast isolations - "normals"
Oral/pharyngeal swab
Saliva/mouthwash
Imprint culture
Overallc
Yeast isolations - patients
Oral/pharyngeal swab
Saliva/mouthwash
Imprint culture
Overallc
C. albicans isolation - "normals"
Oral/pharyngeal swab
Saliva/mouthwash
Overallc
C. albicans isolations - patients
Oral/pharyngeal swab
Saliva/mouthwash
Imprint culture
Overallc
Yeast carriage at different agesd
Neonates up to 7 d
Infants aged 1 week
-18 months
Children >18 months
Adults
20
10
3
32
23
9
2
34
16
5
20
21
6
2
32
5
3
3
8
2.0-69.1
25.0-71.3
39.4-50.0
2.0-71.3
12.7-76.2
35.0-75.0
34.0-66.0
12.7-76.2
1.9-41.4
4.3-62.3
1.9-62.3
6.0-69.6
15.4-42.0
43.4-60.0
6.0-69.6
16.9
41.1
46.8
25.5
42.1
52.3
47.0
16.3
29.5
17.7
35.9
33.5
40.6
7.1-31.7 16.3
40.6-54.2 44.1
3.4-36.0
2.0-69.1
8.7
20.3
a Weighted by number of cases in study.
b That is, arithmetic mean of frequencies quoted.
c Including "not stated", etc.
d Based on swab samples only to minimize bias because of sampling method.
From Odds, F. C.: Candida and Candidosis: A Review and Bibliography, 2nd ed., Balliere Tindall,
London (1988).
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Weighted Simple
Range meana meanb Median
27.7
36.8
44.4
34.4
48.3
55.4
54.7
17.6
23.1
17.0
36.6
36.3
38.1
16.0
44.0
6.0
24.5
24.8
40.5
44.6
31.5
45.3
56.2
50.2
17.9
24.2
19.4
36.8
33.5
37.5
17.3
46.3
15.1
25.1
(Rhodotorula, Saccharomyces, etc.) are rare and
transient (Stenderup, 1990).
B. Factors Affecting Candida Carriage
Carriage is more frequent in females than
males, and during the summer months (Barlow
and Chattaway, 1969). The similarities between
carriers and noncarriers of C. albicans with re-
spect to age, caries experience, periodontal status,
and intraoral temperature indicate that many fac-
tors do not significantly influence candidal car-
riage (Arendorf and Walker, 1979). Some factors
that do influence carriage, however include:
1. Salivary Factors
The quality and the quantity of saliva and its
constituents play a critical role in modulating yeast
cell populations in the oral cavity. Lack of sali-
vary flushing action and the absence of antifungal
salivary constituents such as lactoferrin and
lysozyme may help explain the increased oral
yeast carriage and infection seen in xerostomic
patients (MacFarlane, 1990) and in animal mod-
els (Jorge et al., 1983). The correlation between
Candida carrier status and pH on the surface of
the tongue shows that the carriage of yeast is
higher in acidic salivas (Arendorf and Walker,
1979).
2. Temporal Variations
Candida counts increase during sleep but are
reduced by taking a meal and by toothbrushing.
Generally, counts are highest early in the morn-
ing, and, furthermore, where counts are low, the
organisms cannot be isolated except in the early
morning. The early morning saliva sample is also
the most dependable for making a comparison of
the Candida population within and between indi-
viduals (MacFarlane, 1990).
Despite the above observations, early morn-
ing saliva specimens from edentulous subjects
not wearing dentures are consistently low in
C. albicans. This has been attributed to sleeping
without dentures and the consequent alteration in
the oral environment. Davenport (1970) has found
larger numbers of Candida in smears from den-
tures than from mucosa. When dentures are worn
at night, the early morning saliva Candida count
is high; when dentures are not worn at night, the
early morning count is the lowest. The increased
Candida count following reinsertion of the den-
tures suggests that plaque on the dentures harbors
C. albicans (Budtz-Jorgensen, 1990).
The increase in both the frequency of carriage
and the density of candidal colonization in den-
ture wearers compared with dentate subjects sug-
gests that prostheses encourage the presence and
growth of candidal species (Arendorfand Walker,
1979).
3. Smoking
Some studies have suggested that smoking
does not affect Candida carriage significantly
(Bastiaan and Reade, 1982; Oliver and Shillitoe,
1984), while others have reported that smoking
significantly increased carriage by 30 to 70%
(Arendorf and Walker, 1980).
It has been suggested that cigarette smoking
might lead to localized epithelial alterations that
allow colonization by Candida (Arendorf and
Walker, 1980). An alternative hypothesis is that
cigarette smoke provides nutrition for C. albicans.
The related species of C. tropicalis, C. guillier-
mondii, and C. pulcherrima have inducible en-
zyme systems that would allow them to replicate
using polycyclic aromatic hydrocarbons as their
source of carbon and energy (Takagi et al., 1980).
This relationship between cigarette smoke and
Candida is particularly important, as the enzyme
system in question can increase the carcinogenic
activity of the hydrocarbon and candidal
leukoplakia might have a higher potential for
malignant changes than other leukoplakias
(Cawson and Binnie, 1980, also see below).
4. Oral Topography
C. albicans colonizes mainly the posterior
dorsum ofthe tongue (Arendorf and Walker, 1980,
Oliver and Shillitoe, 1984). It may be relevant
that this is the site at which median rhomboid
glossitis occurs, a condition that is usually, if not
always, associated with proliferation of candidal
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hyphae (Walker and Arendorf, 1990). In denture
wearers, the fitting surface of the denture is the
main reservoir of the yeasts (Budtz-Jorgensen,
1990).
5. Immune Status
Carriage of Candida has been shown to be
greater in persons ofblood group0 and nonsecre-
tors of blood group antigens in saliva (Mason
et al., 1988) possibly mediated by an effect on
C. albicans adhesion to epithelia (Blackwell et al.,
1986). Specific antibodies to C. albicans
(Vudhichamnong et al., 1982) and decreasing
T-lymphocyte helper-to-suppressor ratios (Melbye
et al., 1985) may also influence carriage.
6. Oral Microflora
A number of studies have indicated that Can-
dida can be isolated from the oral cavity with
greater prevalence and in greater numbers during
tetracycline therapy (McGoven et al., 1953). Ani-
mal studies have shown that suppression of the
commensal oral flora by diets containing broad
spectrum antimicrobials (e.g., tetracyclines) are a
prerequisite to initiate and establish oral infection
(Fisker et al., 1982), although other studies indi-
cate that antibiotics are not essential for initiation
of oral candidosis in murine models (Allen and
Beck, 1983).
7. Candida Carriage in Hospitalized
Patients
The oral carriage of yeasts is higher in hospi-
talized than ambulant patients (Table 1), with a
median carriage rate of 54.7% for all species and
a median of 38.1% for C. albicans alone.
C glabrata is often found in significant numbers,
with the highest frequency in denture wearers and
those with denture-induced stomatitis (Odds,
1988). In one study of denture wearers without
stomatitis, C. glabrata was found in 48% and
C. albicans in 84%, with an association of the two
species in 41%. High carriage frequencies (up to
78%) are also found in the hospitalized elderly
(Cumming et al., 1990; Wilkieson et al., 1991).
Thus, a consequence of hospitalization is an
increase in carrier rates, but high counts alone do
not necessarily mean that the patient will have
clinical symptoms of candidosis (Mitchell et al.,
1982).
IV. HOST ORAL DEFENSES AGAINST
CANDIDA INFECTION
The host defenses against Candida have been
reviewed recently (Greenfield, 1992). The oral
epithelium acts as a physical barrier, and epithe-
lial turnover per se contributes to defense.
A. Microbial Interactions
Competition and inhibition by the oral flora
are also important in limiting the establishment
and overgrowth of fungi (Epstein et al., 1984).
Microbial interactions include nutritional compe-
tition, alteration in the microenvironment, and
elaboration of toxic and metabolic byproducts.
The indigenous bacterial flora can decrease colo-
nization by C. albicans by competing for adher-
ence sites on epithelial cells (Samaranayake, 1990).
In contrast, Candida may also maintain syn-
ergistic relationships with pathogenic flora. Thus,
synergism between C. albicans and Staphylococ-
cus aureus has been observed (MacFarlane, 1990).
Noteworthy in this context is the co-infection by
Candida spp. and S. aureus in angular stomatitis
(Warnakulasuriya, Samaranayake, and Peiris,
1990).
Alterations in the microbial flora associated
with systemic illness, hormonal changes, and use
of medications (corticosteroids and antibiotics)
may be significant in predisposing to candidosis
(Rogers and Balish, 1980). For example, an in-
creased prevalence of C. albicans in saliva has
been shown in patients treated with antibiotics
and corticosteroids and in diabetic patients (Knight
and Fletcher, 1971).
B. Salivary Nonimmune Factors
1. Iron
Iron is an essential nutrient of both bacteria
and fungi, and Weinberg (1974) noted evidence
that increased susceptibility to infectious agents
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was associated with elevated levels of iron in
serum. In contrast, the iron-binding proteins, in-
cluding lactoferrin, have been shown to inhibit
growth or kill C. albicans (Nikawa et al., 1993).
Samaranayake (1986) has reviewed the role of
iron in oral candidosis.
2. Lysozyme
Lysozyme (muramidase) is a low-molecular-
weight protein present in relatively high concen-
tration in the oral cavity, saliva, gingival crevicular
fluid, and polymorphonuclear leukocytes (Brown
et al., 1975). Lysozyme can, by increasing per-
meability, damage Candida; C. albicans and
C. glabrata are the least sensitive to lysozyme,
whereas C. krusei is the most sensitive (Tobgi
etal., 1988).
Lysozyme has also been shown to stimulate
phagocytosis in association with IgA. The hydro-
lytic action of lysozyme on cell wall structural
proteins, injury to cytoplasmic membranes, ag-
glutination of Candida species, and stimulation
of phagocytosis indicate a significant role for
lysozyme in host defense in oral candidosis (Hill
and Porter, 1974).
3. Salivary Histidine-Rich Polypeptides
Salivary histidine-rich polypeptides (HRPs),
together with antimicrobial proteins such as
lysozyme, are antifungal and in healthy individu-
als suppress Candida levels (Rayhan et al., 1992).
4. Lactoferrin
Lactoferrin is found in parotid and subman-
dibular saliva and in polymorphonuclear leuko-
cytes, and concentrations in saliva increase
dramatically during inflammation of the oral
mucosa and parotid gland (Tabak et al., 1978). Its
antifungal activity is believed to be because of
binding of iron (Soukka et al., 1992). Lactoferrin
has also been postulated to enhance the antibacte-
rial activity of lysozyme by attenuating the in-
hibitory effect of iron on this enzyme (Masson
and Heremans, 1971). Furthermore, as with
lysozyme, there appear to be interspecies and in-
traspecies variations in the sensitivity of Candida
to lactoferrin (Nikawa et al., 1993). The latter
group has demonstrated that lactoferrin may con-
fer structural changes on the cell walls of Can-
dida and have demonstrated bleb-like cell wall
modifications in lactoferrin-treated yeasts.
5. Lactoperoxidase
The lactoperoxidase (LPO) system in the
mouth possesses antimicrobial activity (Tenovuo
et al., 1977) involving multiple factors (H202 and
halides) and modes of action, including halogena-
tion of microbial proteins, aldehyde formation,
and oxidation of lipid sulfydryl groups (Klebanoff,
1974). Significant candidacidal activity was dem-
onstrated when Candida organisms were incu-
bated with a conjugate oflactoperoxidase, xanthine
oxidase, and specific antibody against Candida
(Okuda et al., 1980).
6. Salivary Glycoproteins
Salivary glycoproteins antigenically similar
to host cell surface antigens (blood group anti-
gens) affect competition and prevent surface ad-
herence of microbes to the mucosal surface; this
results in augmentation of the cleansing action of
saliva (MacFarlane, 1990; also see below).
C. Immune Factors in Host Defense
Against Candida
1. Granulocytes
Bone marrow-derived cells, probably neutro-
phils, are crucial to the natural resistance to
C. albicans (Ashman and Papadimitriou, 1990).
Individual granulocytes can phagocytose up to 10
yeasts (Pereira and Hosking, 1984), but the pro-
portion killed remains constant at about 20 to
30% regardless of the number ingested. The
myeloperoxidase (MPO)-hydrogen peroxide-ha-
lide system appears to play a major role in the
intracellular killing of Candida (Lehrer and Cline,
1969). Susceptibility to candidal and staphylo-
coccal infection has been the chief problem re-
sulting from MPO deficiency (Lehrer and Cline,
1969). Okuda et al. (1991) reported a case of
alveolar pyogenic granuloma in the maxilla caused
by infection with C. albicans in a patient with
MPO deficiency.
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The candidacidal activity of human neutro-
phils has been shown to be enhanced indepen-
dently by immune interferon (IFN-a) and tumor
necrosis factor (TNF) (Djeu et al., 1986). In the
presence of suboptimal levels of IFN-a, TNF acts
synergistically to increase neutrophil effector func-
tion. Cytokines such as granulocyte colony-stimu-
lating factor (G-CSF) can increase production of
neutrophils by bone marrow and increase resis-
tance to C. albicans (Matsumoto et al., 1987).
Granulocytes can also kill the mycelial elements
of Candida, and the capacity to bind and to gen-
erate microbicidal oxidants is augmented by se-
rum opsonins (Diamond, 1988).
2. Cell-Mediated Immunity
Although phagocytosis represents the prime
mechanism by which C. albicans is controlled,
the intrinsic candidacidal abilities of both granu-
locytes and macrophages are quite limited, and
full expression of their effect is dependent on
augmentation by cytokines sythesized or induced
by T cells (Ashman and Papadimitriou, 1990).
Candida infections are consistently seen when
cell-mediated immunity is depressed (Valder et al.,
1987). Lymphokine production by T cells is ini-
tiated by an antigen-specific interaction. This pro-
cess involves antigen processing and presentation
by macrophages or other accessory cells that carry
appropriate (compatible) class I and class 2 MHC
antigens on their surface. In this context, it is
significant that human Candida-specific T cells
require HLA-DR-compatible macrophages for
their activation (Jose et al., 1981), and that Can-
dida infection markedly increases the expression
ofHLA-DR and HLA-DQ antigens on the surface
membranes of epithelial cells (Jontell et al., 1986).
Activation of T cells produces a wide range
of lymphokines that can, in turn, modulate the
functions of macrophages and other leukocytes.
Interferon-gamma (IFN-,y) is the only lymphok-
ine known to increase the microbicidal activities
of macrophages: it also initiates TNF synthesis by
them (Papadimitriou and Ashman, 1989). In the
presence of suboptimal levels of IFN-y, Candida
killing by neutrophils is markedly enhanced by
TNF. Unfortunately, the cytokines produced as a
result of T cell/macrophage interactions have the
potential to exacerbate symptoms of illness as
well as enhancing clearance of the infection
(Ashman and Papadimitriou, 1990).
Polysaccharide antigens of C. albicans may
generate a complex series of interactions that
suppress both T- and B-cell responses (Piccalella,
Lombardi, and Morelli, 1981). These effects may
eventually block the synthesis of both interleukin
2 (IL-2) and IFN-y, as well as the expression of
the Tac antigen (the IL-2 receptor) by normal T
cells (Lombardi et al., 1986); antigen presenta-
tion and interleukin 1 (IL-1) production by mono-
cytes may also be affected (Lombardi et al.,
1985).
3. Humoral Immunity
Serum antibodies can affect the growth of
C. albicans (Grappel and Calderone, 1976). The
major specific immunologic factor in saliva is
sIgA, which may be a primary defense against
oral candidosis by aggregating the organisms and
by preventing their adherence to mucosal epithe-
lium (Epstein et al., 1982).
Humoral- and cell-mediated immunity to
C. albicans may comprise a second line of de-
fense when penetration of mucosa or systemic
infection occurs. Wilton and Lehner (1980) re-
ported that both mucocutaneous and systemic
candidosis are typically associated with defects in
the cell-mediated immune response. These can be
caused by deliberate immunosuppression (as in
transplant patients) or in cancer patients treated
with cytotoxic drugs; they can be associated with
some underlying disease, such as the human im-
munodeficiency virus (HIV) infection, or they
may reflect specific deficiencies in the cell-medi-
ated immune response, as in chronic mucocutane-
ous candidosis (Kirkpatrick, 1988).
4. The Relationship Between C. Albicans
And Heat Shock Protein 90
Prokaryotic and eukaryotic cells respond to
the stress of sudden rise in temperature by in-
creasing the rate of synthesis of so-called "heat
shock proteins" (HSPs) (Lindquist and Craig,
1988). HSP90, together with its breakdown prod-
ucts, is now recognized as an immunodominant
antigen in fungal infections, and seroconversion
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to it is associated with recovery from systemic
candidosis (Burnie and Matthews, 1991).
Sera from patients with culture-confirmed
systemic candidosis contain detectable antibodies
against C. albicans, but whereas survivors pro-
duce a major antibody response to the 47-kDa
antigen of Candida, fatal cases produce little or
no antibody (Matthews et al., 1987). The 47-kDa
antigen is a heat-stable breakdown product of the
larger 92-kDa antigen that circulates in the sera of
these patients (Matthews et al., 1987). The 92-kDa
antigen is a heat shock protein HSP90 (Matthews,
1992). Antibody to the 47-kDa antigen is also
present in patients with chronic mucocutaneous
candidosis (CMC) and in those with AIDS
(Matthews, 1992; Burford-Mason, et al., 1987).
If the antibody to the 47-kDa antigen is protec-
tive, this would help explain the rarity with which
such patients develop systemic candidosis, despite
severe superficial candidal infections (Matthews,
1992). Indeed, in a neonate with Candida menin-
gitis, who recovered, antibody to the 47-kDa an-
tigen was the first antibody to appear in the
cerebrospinal fluid (Burnie et al., 1986).
C. albicans HSP90 shows >50% direct ho-
mology with human HSP90. Most of the antibod-
ies produced by infected patients were directed
against highly conserved epitopes shared with
human HSP90. Therefore, autoreactive antibod-
ies are produced commonly in patients recovering
from systemic candidosis without any clinical
evidence of autoimmune sequelae (Matthews,
1992).
Human HSP90 is essentially intracellular,
whereas candidal HSP90 circulates in the plasma
in large amounts (Matthews, 1992). A pathogenic
effect resulting from candidal HSP90 might be
the disseminated intravascular coagulation some-
times associated with systemic candidosis (Rebbe
et al., 1987). Antibody to HSP90 would then be
protective because it neutralizes the activity ofthe
extracellular fungal HSP90. The possible role of
HSP90 in candidosis is discussed fully elsewhere
(Matthews, 1992).
V. PATHOGENICITY OF CANDIDA
SPECIES
The factors involved in the pathogenicity of
C. albicans have been reviewed recently (Krempl-
Lamprecht, 1991). The pathogenesis of different
biotypes and strains of C. albicans varies (Allen
and Beck, 1983).
A. Enzymes of Candida
It has been suggested that C. albicans pro-
duces an "endotoxin" (Dobias, 1964), but the lev-
els ofendotoxin found in vivo may not be sufficient
to produce toxic effects (Cutler et al, 1972). Al-
ternatively, the organisms may produce enzymes
that facilitate penetration of the mucous mem-
branes (Arendorf and Walker, 1979). Candida
certainly has the ability to produce phospholi-
pases and Pugh and Cawson (1977) have shown
that the phospholipases are concentrated at the
tips of fungal hyphae and localized in the vicinity
of host cellular compartments where active inva-
sion is occurring. These enzyme activities were
found in most C. albicans strains but not in or-
ganisms known to be less virulent than C. albicans
(Samaranayake et al., 1984b), such as C. glabrata,
C. tropicalis, and C. parapsilosis.
Extracellular proteinases have also been im-
plicated in the pathogenicity of C. albicans
(MacDonald and Odds, 1980). Proteinase-defi-
cient strains are noninvasive (MacDonald and
Odds, 1983), and the pattern of adherence also
reflects the expression of secretory proteinase
(Borg and Ruchel, 1988). Salivary proteins, in-
cluding IgA, can be almost completely degraded
by acidic proteinases of Candida especially under
low pH conditions (Samaranayake et al., 1993).
Recently, it has been shown that parotid saliva is
more resistant to the proteolytic action of Can-
dida proteinase when compared with mixed sa-
liva (Samaranayake et al., 1993). Acid proteinase
(aspartyl proteinase) production is increased by
C. albicans isolated from later stages of HIV in-
fection and may contribute to candidosis. The
role of alkaline proteinase in the oral cavity is not
clear yet.
B. Temperature Variations
The virulence of C. albicans can also be in-
fluenced by the temperature at which it is grown
(Hazen and Hazen, 1987). Virulence is associated
with increased germ tube production by yeast
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grown at the lower temperature. These, in turn,
display enhanced adherence characteristics com-
pared with the parent yeasts mainly in the blas-
tospore phase (Tronchin et al., 1988). Yeasts
grown at room temperature are more resistant to
killing by polymorphonuclear leukocytes (Antley
and Hazen, 1988). The clinical implications of
these phenomena, if any, is not known.
C. Adhesion of Candida
There is a vast literature on this topic, which
is excellently reviewed by Kennedy (1988). A
relationship has been suggested between the ad-
herence of C. albicans to surfaces and its ability
to colonize and cause disease (Odds, 1988). An
important aspect of the pathogenicity of
C. albicans may be its nonspecific affinity and
binding to acrylic resin (Candida-associated den-
ture stomatitis) and other plastics (catheter-re-
lated candidosis) (Shepherd et al., 1985). The
mechanism of attachment is believed to involve
the interaction of cell wall components of
C. albicans with the target surface (McCourtie
and Douglas, 1984).
The initial yeast to epithelium contact may be
due to nonspecific adhesion followed by specific
adhesion (Sandin, 1987). Modification of both
host and yeast cells have been observed once
C. albicans is attached. It may be that the Can-
dida cells "bump" into epithelial cells, initially
binding reversibly and then physiological changes
strengthen the adhesion. These changes could
modify the epithelium to the extent that more, or
different, receptors are exposed that stabilize and
strengthen adhesion (Tronchin et al., 1984). It has
also been suggested that the adhesion of
C. albicans to oral mucosal cells might entail in-
teractions involving divalent cations (Kennedy,
1988). The adsorption of macromolecules onto
epithelial cells is believed to occur via electro-
static interactions involving calcium ions and other
ionic groups. Candida cells might also attach by
similar mechanisms.
The extent and strength of the adhesion de-
pends on the initial surface properties of both the
organisms and substratum involved and can be
influenced by several factors (Rutter, 1984). These
are listed in Table 2.
The cell surface structures promoting adhe-
sion are highly dependent on the culture condi-
TABLE 2
Factors Affecting Adhesion of Yeasts
Factors related to yeast cells
Medium/cultivation
Phenotype
Germ tubes/hyphae
Extra-cellular polymeric material (EP)
Floccular/fibrillar surface layers
Mannan
Chitin
Hydrophobicity
Cellular lipids
Factors related to host cells
Cell source
Mucosal cell size and viability
Fibronectin
Fibrin
Sex hormones
Yeast carriers vs. patients with overt candidosis
Environmental factors affecting adhesion
Cations
pH
Sugars
Saliva
Humoral antibody and serum
Antibacterial drugs
Bacteria
Lectins
tions of the yeast. Optimal adhesive activity of
C. albicans is seen only when the cells are grown
in defined media at 250C (Kennedy, 1988). It has
also been observed that the phenotypic variant,
"white" cells of Candida are significantly more
adhesive to buccal epithelial cells than are
"opaque" cells (Kennedy et al., 1988). The adher-
ence of the hyphal phase of C. albicans to cells is
significantly greater than that of the blastospore
phase cells (Samaranayake and MacFarlane,
1982; Tronchin et al., 1988) so that conditions
conducive to germ tube formation result in sig-
nificantly greater adherence (Sobel et al., 1981).
It is not clear why viable germ tubes enhance
adherence, but it has been suggested that there
may be changes in surface components such as
adhesins that could account for the increased
adherence (Kimura and Pearsall, 1978; Tronchin
et al., 1988). Further, germ tubes promote clump-
ing of yeast cells and binding of adjacent fila-
ments, thus bringing a larger number of Candida
organisms into contact with epithelial cells (Sobel
etal., 1981).
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It is possible that sterols may be involved in
adhesion mechanisms; the role of lipids is re-
viewed elsewhere (Mishra et al., 1992).
The extracellular polymeric material (EP)
originating from the yeast cell surface appears
important in facilitating adhesion. EP originating
from the cell surface of C. albicans contains sur-
face glycoproteins responsible for yeast adhesion,
and it is thought that the protein portion of the
mannoprotein is probably more important than
the carbohydrate moiety (Critchley and Douglas,
1987).
There are at least two surface types of Can-
dida adhesin: floccular and flbrillar (Kennedy,
1988). Whereas the floccular layer mediates ad-
hesion to oral mucosal epithelium, isolates that
are able to synthesize a fibrillar surface layer
demonstrate increased adhesion to epithelial cells
(McCourtie and Douglas, 1984).
The interaction of bacteria and fungi on epi-
thelial surfaces has aroused clinical interest for
some time. The indigenous oral flora may inter-
fere with adherence and colonization by Candida
organisms. It has been observed that the normal
resident bacterial flora suppresses fungal coloni-
zation, whereas alteration and reduction in sur-
face bacteria, such as is seen after antibiotic
therapy, are associated with fungal colonization
and often symptomatic disease (Saigh et al., 1978).
Adherence is temperature dependent and can
occur at pH values consistent with those of the
vaginal (pH 5.0) and oral mucosal surfaces
(pH 7.0) (Samaranayake and MacFarlane, 1982).
However, at low pH conditions, pH 3 to 4, the
adherence of Candida to both epithelial and acrylic
surfaces is significantly increased (Samaranayake
et al., 1980).
Secretory immunoglobulin A (sIgA) can in-
hibit the adherence of C. albicans to human oral
epithelial cells (Vudhichamnong et al., 1982).
Chitin derivatives can inhibit the adherence of
C. albicans to acrylic (Segal et al., 1992). The
effect of blood group secretor status is discussed
below.
D. Switching Phenomena
C. albicans frequently exhibits variant colo-
nial forms when grown in vitro. For instance, a
smooth colony-forming yeast when inoculated
onto an agar surface may produce a proportion of
colonies with rough surfaces (smooth to rough
switching). It is known that switching can be
triggered by low doses of UV radiation, and once
triggered into the high-frequency switching mode
C. albicans exhibits high rates of alterations in
colony morphology (Soll, 1992). Thus, C. albicans
has the capacity to switch frequently and revers-
ibly between several variants, heritable, pheno-
types (Soll, 1992). Switching is associated with
changes in micromorphology and physiologic
properties as well as a number of putative viru-
lence traits. One switching system, "white-opaque"
transition, has been examined for the capabilities
of the two phenotypes to adhere to oral epithelial
cells. "White" cells were shown to be signifi-
cantly more adhesive than were "opaque" cells
(Kennedy et al., 1988), and there may be differ-
ences in hyphae and antigenic pattern (Soll, 1992).
It has been postulated that the switching
mechanisms of Candida may help potentiate its
pathogenic features (1) during invasion of differ-
ent body environments, (2) by eluding the im-
mune system by altering its surface antigenicity,
and (3) by escaping the action of antifungals. (For
a recent review of this phenomenon see Soll, 1992.)
VI. FACTORS PREDISPOSING TO ORAL
CANDIDA INFECTIONS
The major local and systemic factors that
predispose humans to candidosis have been clas-
sified by Odds (1988) as natural factors, dietary
factors, mechanical factors, and iatrogenic fac-
tors. Oksala (1990), in a review of literature of the
factors predisposing to oral candidal infection,
listed those shown in Table 3. These are discussed
below.
A. Prostheses
As far as chronic local irritants, ill-fitting
appliances, and inadequate hygiene are concerned,
high salivary yeast counts are much more com-
mon in full-denture wearers than in dentate sub-
jects (Parvinen, 1984). Yeasts are demonstrable
in 78 to 100% of patients with denture-induced
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TABLE 3
Factors Predisposing to Oral Candidosis
Chronic local irritants
III-fitting appliances
Inadequate care of appliances
Disturbed oral ecology or marked changes in the
oral microbial flora by antibiotics, corticosteroids,
xerostomia
Dietary factors
Immunological and endocrine disorders
Malignant and chronic diseases
Severe blood dyscrasias
Radiation to the head neck
Abnormal nutrition
Age
Hospitalization
Oral epithelial dysplasia
Heavy smoking
From Odds, 1988; Kostiala, Kostiala and Kahanpaa,
1979; Petersen, 1984; Oksala, 1990.
stomatitis (Olsen, 1974). However, in microbio-
logical studies of patients with denture-induced
stomatitis, yeast counts usually constituted less
than 1% of the total microbial counts. Nonethe-
less, there was a 10-fold increase in the yeast
counts in denture plaque obtained from denture-
induced stomatitis patients when compared with
healthy controls (Budtz-Jorgensen, 1990).
B. Drug Therapy and Radiation Therapy
It is well known that patients on broad spec-
trum antimicrobial therapy may be predisposed to
alterations in the oral flora. Postantibiotic
stomatitis or glossitis caused by C. albicans are
well recognized (Kennedy and Volz, 1983;
Midtvedt, 1990). Topical, systemic, and aero-
solized corticosteroids are all important in this
respect, and excessive use of antibacterial mouth-
washes can also be followed by oral yeast infec-
tion (Samaranayake, 1990).
Drugs with xerostomic side effects (such as
psychopharmaceuticals) also predispose to oral
candidosis (Kostiala et al., 1979). Xerostomia (in
Sjogren' s syndrome and after radiotherapy) pre-
disposes to marked changes in the oral microbial
flora and candidosis (Epstein et al., 1984).
Xerostomia can, in animal models, predispose to
candidosis (Jorge et al., 1993).
Longitudinal studies of patients undergoing
radiation therapy to the head and neck show sig-
nificant increases in the numbers of Candida spe-
cies on the surface of the tongue, in whole saliva,
and in dental plaque (Brown et al., 1975;
Samaranayake et al., 1988).
C. Dietary Factors
A variety of nutritional factors, including
deficiencies of iron, folic acid, vitamins and diets
rich in carbohydrates, have been implicated in the
pathogenesis of oral candidal infections. Cawson
(1966) was the first to describe an apparent rela-
tionship between iron deficiency and oral
candidosis. Cases of chronic mucocutaneous
candidosis, chronic atrophic candidosis, angular
stomatitis, and atrophic glossitis were reported
with iron-defieciency anemia, and the infection
was difficult to eradicate as long as the iron defi-
ciency remained (Higgs and Wells, 1972). The
iron-dependent in vitro growth stimulation of
Candida is thought to be due to the blocking of
the fungistatic property of transferrin, the iron-
binding protein present in serum (Esterly et al.,
1967). Moreover, iron may also affect the local
host defenses via its modulating role in the activ-
ity of lysozyme and lactoferrin (Samaranayake,
1990).
Iron deficiency may produce an impairment
of iron-dependent enzyme systems, thereby af-
fecting the metabolism and, hence, the kinetics of
the rapidly dividing oral epithelial cells (Rennie,
MacDonald, and Dagg, 1984). Such alterations
may result in an epithelial surface more condu-
cive for the adhesion, growth, and invasion of
Candida (Jacobs and Lord, 1961). Joynson et al.
(1972) demonstrated impaired cell-mediated im-
munity to C. albicans in iron-deficient subjects
both in vivo and in vitro, which were restored
once the iron levels returned to normal. Other
general effects of iron deficiency that may bear a
relationship to oral candidosis include deficient
phagocytosis and antibody production (Wilton and
Lehner, 1981).
Growth of Candida either in saliva or nutrient
media supplemented with dietary carbohydrates
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is accompanied by acid production and a signifi-
cant concomitant reduction in pH to very low
levels (Samaranayake et al., 1983a, 1984a, 1986a;
Shepherd and Sullivan, 1976). The reduced pH
levels may potentiate candidal virulence by en-
hancing its growth, multiplication, and adherence
to host tissues, while activating the acidic pro-
teases and phospholipases of the yeast. Further-
more, the direct cytotoxic effect of the acidic
metabolites may exacerbate the host inflamma-
tory response (Samaranayake and MacFarlane,
1985).
D. ImmunologiclEndocrine Disorders
Studies show that Candida species are more
prevalent in the oral cavity of diabetic patients
than in those of healthy nondiabetic individuals.
A study by Lamey et al. (1988) found no signifi-
cant difference in the prevalence of oral candidal
carriage and infection in diabetic patients vs.
nondiabetics in relation to the ability or inability
to secrete blood group antigens. Other possible
factors such as the ability of Candida to adhere to
the oral tissue rather than inherited ability to se-
crete blood group substances may determine those
parameters in diabetics. For instance, Darwazeh
et al. (1990) have recently shown a significant
increase in the adhesion of Candida to oral epi-
thelial cells of diabetics when compared with a
healthy population.
Fungal infections, particularly pseudomem-
braneous and atrophic candidosis, are common in
patients with HIV infection and other secondary
immunodeficiencies. As a result ofdepressed cell-
mediated immunity or phagocytic immunity,
chronic mucocutaneous candidosis (CMC) can
also be a feature of primary immune defects such
as severe combined immune deficiency syndrome
(SCID) (Porter and Scully, 1990). This is fully
discussed below.
Chronic hyperplastic candidosis may occur
as part of chronic mucocutaneous candidosis, of-
ten with identifiable immunologic or endocrine
abnormalities as major factors. Endocrine disor-
ders have a familial incidence and are found in
children and young adults, particularly in girls.
The most frequently associated endocrine mani-
festations include idiopathic hyperparathyroidism
and hypoadrenocorticism, but candidosis follows
only where there is an immune defect (Kostiala
etal., 1979).
E. Malignant Diseases
Host defense mechanisms are impaired by
the malignant process and its chemotherapy, which
in turn can lead to disordered numbers and dys-
function of polymorphonuclear and mononuclear
phagocytes and to oral candidosis (Petersen, 1984;
Kostiala, 1986).
Acute forms of oral mycoses are frequent in
patients with myeloproliferative disease and pro-
vide potential sources for fungal septicaemia
(Kostiala, 1986; Dreizen et al., 1982). C. albicans
is isolated in virtually all episodes of fungal
stomatitis (Kostiala, 1986).
F. Secretory Status
Correlations between blood groups and vul-
nerability to infectious diseases, including mycotic
infections, are well documented (Bird and Tovey,
1982). Blood group antigens are present on mu-
cosal epithelial cells (Bird and Tovey, 1982) and
are found in saliva, gastric secretions, and other
body fluids of most individuals (secretors). It has
been suggested that the nonsecretion of blood
group substances is associated with an increased
susceptibility to oral infection with C. albicans
(Blackwell et al., 1986). The highly significant
excess ofboth blood group0 antigen nonsecretion
among C. albicans carriers suggests it contributes
to the oral carriage in healthy subjects. Blackwell
et al. (1986) found a greater proportion of non-
secretors in patients with oral C. albicans infec-
tions. Mason, Weber, and Willoughby (1988) also
found an excess of nonsecretors among healthy
C. albicans carriers. The blood group H antigen
functions as a C. albicans receptor, and, there-
fore, subjects of blood group 0 (who possess
large quantities of the H antigen on their cell
surfaces) are likely to be the most susceptible to
candidal colonization and subsequent infection
(Mason, Weber, and Willoughby, 1988). In addi-
tion, Lewis blood group antigen, found predomi-
nantly on the cells of nonsecretors, might act as a
receptor for Candida species (May, Blackwell,
and Weir, 1989).
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In a study by Lamey et al. (1991), it was
suggested that secretor status may be an impor-
tant factor in the development of chronic
hyperplastic candidosis.
VIl. CLASSIFICATION AND CLINICAL
MANIFESTATIONS OF ORAL CANDIDA
INFECTIONS
All forms of oral candidosis are considered
opportunistic, and the epithet "disease of the dis-
eased" has been applied to these infections. Nev-
ertheless, it is often difficult to identify the exact
predisposing factor despite intensive investiga-
tions (Samaranayake and Lamey, 1988). This,
together with the varied clinical presentation of
oral Candida infections, has made the task of
disease classification somewhat difficult and com-
plicated.
A. Classification
By tradition, the most frequently adopted
classificaion of oral candidosis has been acute
pseudomembranous candidosis (thrush), acute
atrophic candidosis, chronic hyperplastic
candidosis, and chronic atrophic candidosis.
Chronic hyperplastic candidosis was further
subdivided into four groups based on localization
patterns and endocrine involvement as chronic
oral candidosis (candidal leukoplakia), endocrine
candidosis syndrome, chronic localized mucocu-
taneous candidosis, and chronic diffuse candidosis.
Samaranayake and Yaacob (1990) noted that
the last subdivision of chronic hyperplastic
candidosis generates some confusion, particularly
because it lumps together hyperplasias that are
localized in the oral cavity alone as well as
hyperplasias related to oral manifestations of
mucocutaneous candidoses. However, a dichoto-
mous classification that highlights and catego-
rizes candidosis confined to oral and perioral
tissues (primary oral candidosis) into one group,
and candidal lesions distributed in other parts of
the body as well as the oral cavity in another
(secondary oral candidosis) may be less confusing.
Basically oral candidosis can be categorized as:
Category L: candidal infections confined to oral
and perioral tissues (primary oral candidoses)
(Table 4)
Category II: disorders where oral candidosis is a
manifestation of generalized systemic muco-
cutaneous candidal infection (secondary oral
candidoses) (Table 5);
Cheilo-candidosis and chronic multifocal
candidosis are two further clinical entities that do
not fall exactly into any ofthe candidosis categories.
Cheilo-candidosis presents as a chronic, ul-
cerative granulating lesion of the vermilion area
of the lower lip; chronic multifocal candidosis
has been described as causing chronic, eryth-
ematous plaque-like lesions in at least two of the
following sites: mouth, palate, and dorsum of
tongue (Holmstrup and Besserman, 1983;
Samaranayake and Lamey, 1988).
Following is a brief account of the clinical
variants that comprise primary oral candidoses.
Pseudomembranous, erythematous, and hyper-
plastic candidoses are described first, while Can-
dida-associated lesions such as denture-induced
stomatitis, angular cheilitis, and median rhom-
boid glossitis, with a possible fungal and/or bac-
terial etiology, are described subsequently, Finally,
a note on multifocal oral candidosis and systemic
Candida infections with oral manifestations (i.e.,
secondary oral candidoses) is given.
A. Pseudomembranous Candidosis
Oral candidosis in the form of thrush is clas-
sically an acute infection, but it may recur for
many months or even years in patients using cortico-
steroids topically or by aerosol, in HIV-infected
individuals, and in other immunocompromised
patients. The term chronic pseudomembranous
candidosis has been used for chronic recurrence
of the disease, although this term is not widely
accepted (Proceedings of the Second World Work-
shop in Oral Medicine, Chicago, 1993, in press).
Thrush may be seen in neonates and among
terminally ill patients (Finlay, 1986), particularly
in association with serious underlying conditions
such as leukemia and other malignancies, and is
increasingly seen in HIV disease (Kostiala et al.,
1982; Samaranayake, 1990b; Scully, 1988).
Thrush is characterized by white patches on
the surface of the oral mucosa, tongue, and else-
where. The lesions develop and form confluent
plaques that resemble milk curds and can be wiped
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TABLE 4
Classification of Oral Candidosis
Human Candida mycoses
... Systemic candidoses
Superficial candidoses
... Genital infections (e.g., vulvovaginal)
... Dermal infections (skin and nails)
... Aural and ocular infections
Oral candidoses
Primary oral candidoses
(Group I)
Acute
Pseudomembranous
Erythematous
Secondary oral candidosesa
(Group 11)
Oral manifestations of systemic
mucocutaneous candidoses (due to
diseases such as thymic aplasia and
candidosis endocnnopathy syndrome)
Chronic
Pseudomembranous
Erythematous
Hyperplastic
Plaque-like
nodular
Candida-associated lesions
Denture stomatitis
Angular cheilitis
Median rhomboid glossitis
a See Table 5.
From Samaranayake and Yaacob, 1990; Holmstrup and Axell, 1990; Samaranayake,
1991.
off to reveal a raw, erythematous and sometimes
bleeding base (Odds, 1988). The plaques in oral
thrush are made up of necrotic material and desqua-
mated parakeratotic epithelia, penetrated by
C. albicans yeast cells and hyphae that invade as
far as the stratum spinosum. Edema and
microabscesses containing polymorphonuclear
leukocytes (PMNL) are found in the outer layers
of epithelium. The deeper parts of the epithelium
show acanthosis, and the inflammatory response
in the connective tissue comprises lymphocytes,
plasma cells, and PMNL (Cawson, 1965; Odds,
1988).
A possible complication of oropharyngeal
trush is the involvement of the adjacent mucosa,
particularly those of the upper respiratory tract
and the esophagus. The combination of oral and
esophageal candidosis is particularly preva-
lent in HIV-infected patients (Holmstrup and
Samaranayake, 1990).
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TABLE 5
Classification of Oral Candidosis
Subgroup Condition Onset
Affected sites and
clinical features
Familial chronic
mucocutaneous
candidosis
Diffuse chronic
mucocutaneous
candidosis
Candidosis
endocrinopathy
syndrome
Familial
mucocutaneous
candosis
Severe combined
immunodeficiency
Di George's
syndrome
Chronic
granulomatous
disease
Acquired
immunodeficiency
syndrome (AIDS)
First decade of life
Before 5 years of
age
By second decade
In the first year
of life
Childhood
Any age
Mouth, nails, skin, mainly
chronic hyperplastic lesions
Mouth, nails, skin, eyes,
pharynx and larynx:
chronic hyperplastic lesions
Mouth: associated with
hypoparathyroidism,
hyppothyroidism,
hypoadrenocorticism and
diabetes mellitus; chronic
hyperplastic lesions
Mouth, nails, scalp,
flexures; chronic
hyperplastic lesions
Oral mucosa, skin, nails;
pseudomembraneous or
hyperplastic lesions
Oral mucosa, esophagus;
may manifest as
pseudomembraneous,
erythematous, or
hyperplastic lesions
Note: Group I: These are rare disorders (except Subgroup 6), where candidosis
remains superficial; patients usually do not die from disseminated candidosis.
B. Erythematous (Atrophic) Candidosis
Erythematous or atrophic candidosis is an
uncommon and poorly understood condition as-
sociated with corticosteroids and topical or sys-
temic broad spectrum antibiotics or HIV disease.
It may arise as a consequence of persistent acute
pseudomembranous candidosis when the pseudo-
membranes are shed, may develop de novo
(Lehner, 1967), or in HIV infection may precede
pseudomembranous candidosis (Pindborg and
Nielsen, 1989).
The clinical presentation is characterized by
erythematous areas generally on the dorsum of
the tongue, palate, or buccal mucosa. Lesions on
the dorsum of the tongue present as depapillated
areas. Red areas are often seen in the palate in
HIV disease. There can be an associated angular
stomatitis (Kostiala et al., 1979).
Holmstrup and Axell (1990) noted that the
term "atrophic" used to describe the red areas
could be a misnomer, as redness may be caused
not only by reduced epithelial thickness atro-
phy but also by increased vascularity. Hence,
they suggested that the term "atrophic candidosis"
should be replaced by "erythematous candidosis"
in a new classification of oral candidosis
(Holmstrup and Axell, 1990).
C. Hyperplastic Candidosis (Candida
Leukoplakia)
Candida leukplakias are chronic, discrete
raised lesions that vary from small, palpable, trans-
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1
2
3
4
5a
5b
5c
6
lucent, whitish areas to large, dense, opaque
plaques, hard and rough to the touch (plaque-like
lesions). Homogeneous areas or speckled areas
can be seen, which do not rub off (nodular le-
sions). Speckled leukoplakia counts for 3 to 50%
of all candidal leukoplakias, and they are often
symptomatic. Candida leukoplakias usually oc-
cur on the inside surface of one or both cheeks,
less often on the tongue (Cawson and Lehner,
1968; Arendorf et al., 1983). Biopsy is important,
as the condition is premalignant and shows vary-
ing degrees of dysplasia (Samaranayake, 1990a;
Daftary et al., 1972). Oral cancer supervenes in 9
to 40% of candidal leukoplakias compared with
the 2 to 6% risk of malignant transformation cited
for leukoplakias in general (Banoczy, 1977). The
risk of carcinoma developing in candidal
leukoplakia will depend on whether the lesion is
speckled or homogeneous, the presence and de-
gree of epithelial dysplasia, and the management
adopted (Field et al., 1989).
The histopathology of candidal leukoplakia
includes parakeratosis and epithelial hyperplasia
and Candida invasion restricted to the upper lay-
ers of epithelium (Arendorf et al., 1983; Daniels
et al., 1985). In a minority of cases, the condition
has been associated with iron and folate deficien-
cies and with defective cell-mediated immunity
(Jenkins et al., 1977; Walker and Arendorf, 1990).
D. Candida-Associated Denture
Stomatitis (Denture-induced Stomatitis,
Denture Sore Mouth, Chronic Atrophic
Candidosis)
The characteristic presenting signs of den-
ture-induced stomatitis are chronic erythema and
edema of the mucosa that contacts the fitting
surface of the denture. The mucosa below lower
dentures is hardly ever involved.
The patient may occasionally experience slight
soreness but is usually free of symptoms. The
only presenting complaint may be an associated
anglular stomatitis (Scully, 1986). Dorey and
Blasberg (1985) found that 28% of patients were
aware of a burning or tingling sensation under
dentures, but the remainder were asymptomatic.
Newton (1962) classified denture-induced
stomatitis into three clinical types: type I, a local-
ized simple inflammation or a pinpoint hyper-
aemia; type II, an erythematous or generalized
simple type presenting as more diffuse erythema
involving a part of, or the entire, denture-covered
mucosa, and type III, a granular type (inflamma-
tory papillary hyperplasia) commonly involving
the central part of the hard palate and the alveolar
ridge.
Histologic examination of the soft tissue be-
neath dentures has shown proliferative or degen-
erative responses (Razek and Shaaban, 1978) with
reduced keratinization and thinner epithelium
(Watson and MacDonald, 1982). Dentures can
also produce other changes: the oral flora may be
altered and plaque collects between the mucosal
surface of the denture and the palate. In addition,
the saliva that is present between the maxillary
denture and the mucosa may have a lower pH
than usual (Burket, 1977).
The generalized simple and the granular types
of denture-induced stomatitis are most often
caused by the accumulation of microbial plaque
(bacteria or yeasts) on and in the fitting surface of
the denture and the underlying mucosa (Arendorf
and Walker, 1979; Budtz-Jorgensen, 1974). When
Candida is involved, the more common terms
"Candida-associated denture stomatitis", "den-
ture-induced candidosis", or "chronic atrophic
candidosis" are used. Denture-induced stomatitis
is not exclusively associated with Candida, how-
ever, and, occasionally, other factors such as bac-
terial infection, mechanical irritation, or an allergic
reaction to the denture base material may be im-
plicated (Budtz-Jorgensen, 1990). Nonetheless,
there are no clinical criteria that can reliably dis-
tinguish between a Candida-associated, a bacte-
rial-induced, a trauma-induced denture stomatitis,
or an allergic reaction to the denture base material
(Budtz-Jorgensen, 1990). The high proportion of
women to men sufferers is more likely because of
the higher incidence of edentulism among women
and because of the tendency for women to seek
dental treatment more often than men (Dorey and
Blasberg, 1985).
Patients with denture-induced stomatitis do
not have any serious cell-mediated immune de-
fects, but they may be deficient in migration-
inhibition factor and may have overactive
suppressor T cells or other T-lymphocyte/phago-
cyte defects (Iacopino and Wathen, 1992).
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E. Angular Stomatitis (Perleche, Angular
Cheilitis)
This is a clinical diagnosis of lesions that
affect the angles of the mouth, characterized by
soreness, erythema, and fissuring, and is com-
monly associated with denture-induced stomatitis
(Cawson, 1966; Budtz-Jorgensen, 1990). Both
yeasts and bacteria (especially Staphylococcus
aureus) are involved, as interacting, predisposing
factors (Cawson, 1966; Budtz-Jorgensen, 1974;
Warnakulasuriya, Samaranayake and Peiris, 1991).
However, angular stomatitis is, very occasion-
ally, an isolated initial sign of anemia or vitamin
deficiency, such as vitamin B 12 deficiency, and
resolves when the underlying disease has been
treated (Scully and Cawson, 1987). Iron defi-
ciency anemia and other vitamin deficiencies
have been cited as other predisposing factors
(Samaranayake, 1986). In uncommon condi-
tions, such as orofacial granulomatosis, up to
20% of individuals have angular stomatitis, al-
though Candida species are not often isolated
(Samaranayake and Lamey, 1988). Angular
stomatitis may also be seen in HIV disease
(Samaranayake and Holmstrup, 1989).
Few authors consider that the lesion results
solely from maceration due to deep, occlusive
folds of skin at the mouth angles in individuals
with facial height reduced by old age or edentia
(Chernosky, 1966).
F. Median Rhomboid Glossitis
Midline glossitis, or glossal central papillary
atrophy, is characterized by an area of papillary
atrophy that is elliptical or rhomboid in shape,
symmetrically placed centrally at the midline of
the tongue, anterior to the circumvallate papillae.
Occasionally, median rhomboid glossitis presents
with a hyperplastic exophytic or even lobulated
appearance. The relevance of Candida to the con-
dition has been controversial, with some authors
claiming that the Candida causes the condition,
particularly the papillary atrophy (Tapper-Jones
et al., 1980). Histopathologically, candidal hy-
phae infiltrate the superficial layers of the
parakeratotic epithelium and a polymorphonuclear
leukocyte infiltrate occupies the epithelium, with
elongated hyperplastic rete ridges and a lympho-
cyte infiltration in the corium (Walker and
Arendorf, 1990). However, it has been demon-
strated that the condition frequently shows a mixed
bacterial/fungal microflora (Escobar, Farman, and
Arm, 1984).
G. Chronic Multifocal Oral Candidosis
This term has been given to chronic candidal
infection that may be seen in multiple oral sites,
with various combinations, including (1) angular
stomatitis that is unilateral or bilateral and en-
countered mainly in denture wearers, (2)
retrocommissural leukoplakia that is the most
constant component of the tetrad, (3) median rhom-
boid glossitis, and (4) palatal lesions (Cernea et al.,
1965; Holmstrup and Besserman, 1983). Holm-
strup and Bessermann (1983) applied the addi-
tional criteria: (1) lesions of more than 1 month
duration; (2) an absence of predisposing medical
conditions; (3) patients who had received radio-
therapy or drugs of the following types were also
excluded: antibiotics, antiinflammatory or immu-
nosuppressive drugs, and cytotoxic or psy-
chotropic agents.
Most patients are adult males and tobacco
smokers in their fifth or sixth decade at presenta-
tion (Cernea et al., 1965; Pindborg, 1980). Anti-
fungal therapy will clear the infection and produce
clinical improvement, but recurrence is common,
unless smoking can be reduced (Holmstrup and
Bessermann, 1983).
H. Oral Candidosis Associated with
Systemic Infections
Candidosis is usually restricted to the skin
and mucous membranes but may occasionally
spread. Systemic forms of candidosis may affect
only one organ or be disseminated (Candida
septicaemia) hematogenously (Odds, 1988).
Whereas the candidoses included in Table 4
(Group I) are limited mainly to the oral cavity, it
is important to recognize that oral candidal infec-
tion can occasionally manifest as a result of sys-
temic complications (Group II or secondary oral
candidoses, Table 5) (Bodey and Anaissie, 1989).
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In immunocompromised patients, however, it
is clear that the majority of patients with
candidaemia have evidence of invasive infection.
For example, up to 30% of all patients with acute
leukemia die with systemic Candida infections
(Carpentier, Kiehn, and Armstrong, 1981). The
usual presentation is a patient with persistent fe-
ver unresponsive to broad-spectrum antibacterial
antibiotics (Odds, 1988).
Vil. CANDIDOSIS AND
IMMUNOCOMPROMISED HOSTS
A few patients have chronic candidosis from
an early age, sometimes with a defineable immune
defect (e.g., chronic mucocutaneous candidosis).
The number of patients immunocompromised by
diseases such as HIV infection, hematological
malignancy, and treatment protocols, including
aggressive cytotoxic therapy, however, has in-
creased during recent years and comprises by far
the largest such group.
A. Chronic Mucocutaneous Candidosis
(CMC)
CMC is the term given to the group of rare
syndromes, sometimes with a defineable immune
defect, in which there is persistent mucocutane-
ous candidosis that responds poorly to topical
treatment. In general the more severe the
candidosis, the greater the likelihood that immu-
nological defects (particularly of cell-mediated
immunity) can be identified (Scully, 1988). The
main types of these rare disorders and their fea-
tures are shown in Table 6 (Scully and Cawson,
1987). Further details are given elsewhere (Porter
and Scully, 1990; Scully and Cawson, 1987).
B. HIV-Related Oral Candidosis
Candida infections, with oral thrush and
esophagitis as frequent clinical manifestations,
are the most common opportunistic infections
encountered in AIDS (Klein et al., 1984;
Holmberg and Meyer, 1986; Samaranayake and
Scully, 1989). Ever since the first clinical defini-
tion of AIDS (1981), the CDC/WHO have recog-
nized candidosis of the mouth, oesophagus,
trachea, bronchi, and lungs as "major" opportu-
nistic infections and important indicator diseases.
Subsequently, in 1986 the Walter Reed Army
Institute of Research (Redfield et al., 1986)
adopted a staging classification of HIV infection,
applicable to adults only, based on HIV-antibod-
ies and virus isolation, chronic lymphadenopathy,
T-helper cells/mm3, delayed hypersensitivity, ap-
pearance of thrush, and other opportunistic infec-
tions (Drouhet and Dupont, 1991).
Also, it has been shown in prospective studies
of HIV-infected patients that the occurrence of an
otherwise unexpected mycosis (typically oral
candidosis) in an HIV-infected individual can be
TABLE 6
Chronic Mucocutaneous Candidosis Syndromes
Type Clinical features
Familial CMC
Diffuse CMC (Candida granuloma)
Candidosis-endocrinopathy syndrome
Candidosis thymoma syndrome
Persistent oral candidosis
Iron deficiency
Severe chronic candidosis
Susceptibility to bacterial infections
Mild chronic candidosis
Hypoparathyroidism
Hypoadrenocorticism
Chronic candidosis
Myasthenia gravis
Hematological disorders
From Scully, C. and R. Cawson, 1987.
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predictive of the subsequent development of full-
blown AIDS (Klein et al., 1984; Sabin et al.,
1992).
Retrospective studies have shown that at least
58 to 81% of all AIDS patients contract a fungal
infection at some time, and 10 to 20% die as a
direct consequence (Holmberg and Myer, 1986).
Clearly, Candida infections appear to be the most
common fungal infection, occurring in at least
75% of HIV-infected patients (Scully et al., 1990).
McCarthy et al. (1991) have shown that 92% of
patients with a diagnosis of AIDS had oral
candidosis, compared with only 24% of HIV-
infected patients who had not developed AIDS.
1. Factors Associated with Increased
Frequency of HIV-Related Oral
Candidosis
The main cause of infection in HIV disease is
the immune impairment, but candidosis is found
approximately three times more frequently in
patients who also have xerostomia (McCarthy
etal., 1991).
Recent studies have shown that oral Langer-
hans cells are infected by HIV (Braathen et al.,
1987) and may also play a role in candidosis.
Candida itself may also induce immunosuppres-
sion, and this can influence the prognosis of HIV
infection (Odds, 1988).
2. Clinical Variants of Oral Candidosis
in HIV Infection
The manifestations of candidal infections in
HIV infection are usually restricted to superficial
candidosis with varying degrees of severity. Al-
though not life-threatening, these infections are
persistent and debilitating (Holmberg and Meyer,
1986). The major clinical variants of oral
candidosis, namely pseudomembranous, eryth-
ematous, and hyperplastic candidoses, have all
been described in HIV-infected individuals, and
it should be stressed that their clinical presenta-
tion is similar to those who are not infected with
HIV.
Thrush (pseudomembranous candidosis), the
most immediately clinically obvious type of
candidosis, may involve any area of the oral mu-
cosa, but most frequently the tongue, hard and
soft palate, and buccal mucosa. Oral thrush can
manifest for a variable time period prior to the
development of Kaposi's sarcoma or other life-
threatening opportunistic infections (Scully et al.,
1990; Holberg and Meyer, 1986).
The erythematous (atrophic) type of oral
candidosis is found predominantly in the palatal
mucosa and dorsum of the tongue (Scully et al.,
1990; Samaranayake and Holmstrup, 1989). Some
have suggested that erythematous candidosis is as
serious a prognostic indicator as pseudo-
membranous candidosis, because the erythematous
form is more difficult to recognize and, hence, is
underdiagnosed (Dodd et al., 1991).
Esophageal candidosis in a person with no
other known cause for diminished resistance to
the disease is also considered indicative of AIDS
(Centers for Disease Control/Classification, 1985).
Esophageal candidosis is notable for its persis-
tence, but dissemination does not appear to re-
sult (Armstrong et al., 1985). Esophageal
candidosis gives rise to dysphagia and
retrosternal discomfort and, in some, tender-
ness on pressing on the sternum. Lack of esoph-
ageal symptoms in a patient with AIDS and
oral candidosis does not, however, exclude
esophageal involvement (Holmberg and Meyer,
1986), which can be diagnosed by endoscopy
(Tavitian et al., 1986).
Also, candidosis presenting as median rhom-
boid glossitis is not uncommon in HIV disease.
Angular stomatitis is not infrequent and its ap-
pearance in a nondenture wearer, particularly if in
a high-risk group or if it is recalcitrant to treat-
ment, now raises the suspicion of the presence of
HIV or other immune defects (Scully et al., 1990;
Samaranayake, 1990b).
Oral candidosis appears also to be a frequent
sign of HIV infection in children. Most children
with perinatal HIV infection develop mucocuta-
neous candidosis in the first year of life, as op-
posed to a small percentage of children who are
diagnosed after this period as having AIDS. There-
fore, in the young infants with HIV infection,
chronic mucocutaneous candidosis may act as a
warning sign for early and severe morbidity (Selik,
Strarcher, and Curran, 1988; Samaranayake,
1990b).
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Histologically, oral candidal infection in HIV-
infected patients frequently shows a remarkably
weak inflammatory reaction; the epithelium may
be invaded by numerous hyphae or pseudohyphae
without the ususal characteristic massive infil-
trate of polymorphonuclear leukocytes. Likewise,
the subepithelial inflammatory reaction is sparse
and contains few or no leukocytes (Greenspan
etal., 1986).
IX. THE POSSIBLE ROLE OF CANDIDA
IN ORAL CARCINOGENESIS
Candida-involved leukoplakias (keratoses) are
often of the nonhomogeneous types (Roed-
Peterson et al., 1970) and untreated, 5 to 10%
may develop into carcinomas (Pindborg, 1980).
However, although the epithelium of the
leukoplakias is invaded by Candida it is unclear
whether the yeasts are causally involved in the
development or transformation of leukoplakia.
Candida albicans is, by far, the species most
commonly isolated, and the biotypes associated
with leukoplakias differ from those isolated from
normal oral cavities (Jepsen and Winther, 1965;
Krogh et al., 1987; Krogh, 1990). Candida types
from nonhomogeneous leukoplakia have higher
nitrosation potentials than others, which might
indicate a possible role of specific types in the
transformation of some leukoplakias (Krogh,
1990). Candida species may be involved in
carcinogenesis by elaborating nitrosamine com-
pounds (Blank et al., 1968; Krogh et al., 1987),
which act either directly on the oral mucosa or
interact with other chemical carcinogens to acti-
vate specified protooncogenes and thereby ini-
tiate oral neoplasia (Field et al., 1989).
Candida leukoplakia is characterized histo-
logically by chronic intraepithelial inflammation
with fungal hyphae invading the superficial lay-
ers of the epithelium (Cawson and Lehner, 1968).
The cellular changes often include hyperplasia,
cellular atypia, mild or severe dysplasia, and in situ
or invasive carcinoma (Cawson and Lehner, 1968;
Pindborg, 1971; Roed-Petersen et al., 1970).
Candida may produce preneoplastic changes
in the oral mucosa in animal models (Franklin
and Martin, 1986) and can act as a tumor pro-
moter (O'Grady and Reade, 1992).
X. LABORATORY DIAGNOSIS OF ORAL
CANDIDOSIS
Systems for identification of yeasts may range
from a few simple tests useful in speciating
C. albicans to a large battery of tests that enables
differentiation of all yeasts of medical and dental
importance. Identification is best accomplished
by using a combination of morphologic features
and biochemical characteristics.
A. Microbiology
Any kind of clinical material (swab, sputum,
etc.) for microscopy or culture should be exam-
ined as quickly as possible, because drying may
impair the viability of yeasts. As quantitative as-
sessment is an important factor in the differentia-
tion between carriers and infected patients,
specimens must be dealt with immediately, or
kept in transport medium and stored in a refrig-
erator, for a maximum period of 24 h. When the
clinical material is received in the laboratory, it is
plated on a suitable culture medium. Frequently,
Sabouraud's dextrose agar is used as a primary
culture medium, although it rarely permits dis-
tinction between different yeast species (Silverman
et al., 1990). For the latter purpose, Pagano-Levin
medium is useful (Samaranayake, MacFarlane,
and Williamson, 1987).
1. Smears
Detection of yeasts in a clinical specimen
should start with direct microscopic examination
of smears from the lesion. After fixation, one
slide is stained by the Gram stain and the other by
the periodic acid Schiff (PAS) technique. Yeast
cells appear dark blue after Gram staining and red
or purple in PAS preparations (Silverman et al.,
1990).
2. Swab
Rubbing a sterile cotton-tipped swab over the
lesional tissue or all surfaces irrespective of the
clinical signs is a useful assay for the presence or
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absence of Candida, but it cannot provide a quan-
titative estimate (Silverman et al., 1990).
3. Imprint Culture Technique
This technique uses a sterile plastic foam pad
of known size (typically 2.5 x 2.5 cm) dipped in
Sabouraud's broth and placed on the suspect
mucosal surface for 60 s. Then the plastic foam is
placed directly on Sabouraud's or Pagano-Levin
agar. Candida density at each site is determined
by a Gallenkamp colony counter and expressed as
colony-forming units per mm2 (CFU mm2)
(Arendorf and Walker, 1979). Arendorf and
Walker (1979), using the imprint culture tech-
nique, surmized that the technique could also be
used to discriminate between the carrier state and
oral candidosis. Thus, according to these work-
ers, colony counts in excess of 30 CFU cm2 of
mucosa in the dentate and 49 CFU cm2 in denture
wearers suggested a candidal infection.
4. Paper Points
C. albicans has been detected previously in
high numbers in the subgingival flora (Slots et al.,
1988) or in the gingival tissues of acute periodon-
tal abscesses (Peterson et al., 1987). An absor-
bent sterile paper point is inserted to the depth of
the pocket and then transferred to a transport
medium (Olsen, 1990). The latter is then
whirlimixed thoroughly, in the laboratory and
plated out on appropriate media.
5. Salivary Culture Technique
This involves requesting the patient to expec-
torate about 2 ml of mixed unstimulated saliva
into a sterile, universal container. The number of
Candida expressed as CFU per milliliter of saliva
is estimated by counting the resultant growth on
Sabouraud's agar (Silverman et al., 1990).
Epstein, Pearsall, and Truelove (1980) have
shown that the quantitative culture of saliva is a
useful adjunct in diagnosis of oral candidosis.
They demonstrated that carriers and patients with
oral Candida can be distinguished reliably (with
95% confidence limits) on the basis of quantita-
tive culture. Patients with clinical candidosis har-
bor greater than 400 CFU of Candida per milliliter
of saliva (Epstein, Pearsall, and Truelove, 1980).
6. Oral Rinse Technique
This consists of requesting the patient to rinse
the mouth for 60 s with 10 ml of sterile phos-
phate-buffered saline (PBS, pH 7.2) or sterile
water. The patient then returns the oral rinse to
the universal container. If the patient wears a
denture, this should be removed prior to sam-
pling. The oral rinse is centrifuged at 1700 x g for
10 min, and the deposit resuspended in 1 ml of
sterile PBS. The concentrated oral rinse is now
inoculated on appropriate media to assess CFU
per milliliter of rinse sample using a Spiral Plater
prior to incubation. The CFU (estimated using a
Gallenkamp colony counter) is multiplied by the
dilution factor to yield the CFU per milliliter of
original oral rinse sample (Samaranayake et al.,
1986b).
The concentrated oral rinse culture technique
has a number of advantages over the imprint tech-
nique. It is simple to perform as it does not in-
volve the clinician in judgement of the sampling
site. In addition to Candida species, a single rinse
sample can be used for quantitation of other or-
ganisms such as coliforms (Samaranayake et al.,
1986b).
7. Commercial Systems
A rapid commercial system (Microstix-Can-
dida and Oricult-N) for diagnosing oral candidosis
is useful for screening patients in the clinical
setting, particularly when microbiology laborato-
ries are not within easy access (Silverman et al.,
1990).
B. Histopathology
Although swabs and smears are essential for
a micobiological diagnosis of a number of types
of oral candidosis when candidal leukoplakia
(chronic hyperplastic candidosis) is suspected, a
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biopsy specimen should be taken. Because Can-
dida species stain poorly by hematoxylin and
eosin, staining with periodic acid Schiff (PAS) or
Gridley's or Gomori's methenamine silver (GMS)
stains are used. In both Gridley's and the PAS
procedure, the fungi appear a pinkish-red. The
GMS technique stains yeast cell walls brown-
black because of deposition of reduced silver.
The presence of blastospores and characteristic
pseudohyphae or hypae in the superficial epithe-
lial tissues identifies the fungus as a species of
Candida. However, as the speciation of the or-
ganism cannot be performed by this means alone,
cultural studies should also be used (Silverman
et al., 1990).
Blastospores similar to those of Candida spe-
cies may be seen in histoplasmosis or crypto-
coccosis, both of which are becoming increasingly
important and may manifest orally with increas-
ing frequency in AIDS patients (Greenspan et al.,
1986). Therefore, if only blastospores of Candida
are seen in tissue sections of suspect patients,
serial sections should be carefully searched for
pseudohyphae or hyphae of Candida species
(Silverman et al., 1990).
C. Immunologic Tests
Immunity in superficial candidosis and in oral
candidosis is predominantly cell mediated (Budtz-
Jorgensen, 1990). Cell-mediated immunity to
C. albicans antigens can be demonstrated in most
human subjects both by the appearance of de-
layed skin hypersensitivy to Candida antigens
and by in vitro tests of cellular immunity such as
inhibition of leukocyte migration or stimulation
of lymphocyte transformation to Candida anti-
gens (Odds, 1988).
As tests of humoral immunity, the Candida
agglutinin test, the Candida complement fixation
test, the Candida precipitin test, immunofluores-
cence, and ELISA tests have been used. In the
serological tests, four principal types of Candida
antigens have been used, namely, whole nonvi-
able yeast cells, Candida culture filtrates, cell
wall polysaccharides or glycoproteins, and cyto-
plasmic antigens from mechanically disrupted
yeast cells. Serologic tests for Candida, however,
are not diagnostic tools, as the diagnosis can be
achieved more readily by clinical evaluation and
by smear or culture (Odds, 1988; Jeganathan and
Chan, 1992).
D. Hematologic Investigations
Because oral candidosis is associated fre-
quently with predisposing factors such as nutri-
tional deficiencies, blood dyscrasias or HIV
disease, estimates ofhemoglobin, lymphocyte and
white blood cell counts, corrected whole blood
folate, vitamin B 12 and serum ferritin can be
important (Scully and Cawson, 1987).
Tests such as lymphocyte function, serum
immunoglobulins, calcium status, or parathyroid
hormone levels are unnecessary except in chronic
mucocutaneous candidosis. Because some endo-
crine disorders may be associated with oral
candidosis, tests of thyroid or adrenocortical func-
tion are warranted in selected individuals (Lamey
and Samaranayake, 1988).
Xi. PROPHYLAXIS OF ORAL
CANDIDOSIS
Those at greatest risk of fungal infection are
patients with HIV disease, receiving cancer che-
motherapy, immunosuppressive therapy, or pro-
longed antibiotic therapy.
Often in the treatment of fungal infection at-
tention to the underlying cause will avoid the
need for prolonged or repeated courses of treat-
ment. If antibiotics or corticosteroids (oral or in-
haled) are the probable cause, reducing the dose
or changing the treatment may help. Intermittent
or prolonged topical treatment may be necessary
where the underlying cause is unavoidable or in-
curable (Drug and Therapeutics Bulletin, 1990).
In patients with severe immunosuppression,
prevention of colonization and infection is the
goal because the oropharyngeal region may be the
primary source of initial colonization and allow
subsequent spread of the infection. In HIV infec-
tion, topical agents will often control the infection
initially until the increasing immune defect ne-
cessitates systemic agents (Epstein, 1990).
Topical antifungal agents are available as
rinses, tablets, vaginal tablets, and creams. Oral
rinses are useful for patients with dry mouth who
may have difficulty in dissolving tablets. How-
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ever, some oral products are sweetened with sugar,
thus predisposing to dental caries (Epstein, 1990).
Denture plaque often contains Candida spe-
cies. Therefore, to prevent denture-induced
stomatitis, denture cleansing that includes removal
of Candida is a necessary and important factor
(Olsen, 1974; Budtz-Jorgensen, 1974). Cleansers
can be divided into groups according to their
main components: alkaline peroxides, alkaline
hypochlorites, acids, disinfectants, and enzymes
(Budtz-Jorgensen, 1990).
Yeast lytic enzymes and proteolytic enzymes
are found to be the most effective against candida
(Tamamato et al., 1985). Denture soak solution
containing benzoic acid completely eradicates
C. albicans from the denture surface as it is taken
up into the acrylic resin and eliminates the organ-
ism from the internal surface of the prosthesis
(lacopino and Wathen, 1992). Kamalakshi et al.
(1992) have shown the effectiveness of an oral
rinse containing 0.12% chlorhexidine gluconate
in complete elimination of C. albicans from the
acrylic resin surface of the denture, and in reduc-
tion of palatal inflammation. A protease-contain-
ing denture soak (alcalase protease) is also an
effective way of removing denture plaque, espe-
cially when combined with brushing (Odman,
1992).
XII. TREATMENT OF ORAL CANDIDOSIS
Antifungal chemotherapy has been reviewed
recently (van den Bossche, 1991; Graybill, 1992;
Rinaldi, 1992).
A. Polyene Antifungal Agents
The polyene agents are derived from Strepto-
myces species; they include nystatin and
amphotericin (Epstein, 1990; Lewis et al., 1991).
1. Nystatin
Nystatin was the first specific polyene anti-
fungal agent effective in the treatment of
candidosis. Nystatin, if swallowed, may lead oc-
casionally to gastrointestinal side effects such as
nausea, vomiting, and diarrhea (Epstein, 1990;
Lewis et al., 1991; Drug and Therapeutics Bulle-
tin, 1990). However, when given parenterally, the
toxicity and insolubility have limited it to topical
use in a rinse form, oral and vaginal tablets or
creams. The medications have to be applied four
times daily, 500,000 units for adults and 100,000
for children. Higher doses may be required in
immunocompromised patients.
2. Amphotericin
Amphotericin binds to the membrane sterols
of fungal cells, causing impairment of their bar-
rier function and loss of cell constituents
(Warnock, 1991). It has a broad spectrum of ac-
tion that includes most of the major fungal patho-
gens of man.
The use of amphotericin for oral infections is
usually limited to topical application (oral sus-
pension 100 mg/ml, lozenges 10 mg) (Epstein,
1990; Lewis et al., 1991; Drug and Therpeutics
Bulletin, 1990). Occasional strains of C. albicans
resistant to amphotericin are now being reported
(Conly et al., 1992).
Amphotericin is not absorbed from the gut,
and although it can be given intravenously (for
systemic candidosis) there is a considerable risk
of toxicity, which may manifest as fever, vomit-
ing, and renal, bone marrow, cardiovascular, and
neurological toxicity.
B. Azole Agents
These synthetic antifungals, subdivided into
imidazoles and triazoles, are the first broad spec-
trum agents active against a number of yeasts.
Their fungistatic property is due to the changes in
the permeability of the yeast cell cytoplasmic
membranes. The currently available imidazoles
are clotrimazole, miconazole, econazole, and
ketoconazole, while fluconazole and itraconazole
are the more recently introduced triazoles (Epstein,
1990; Bodey, 1992).
1. Clotrimazole
Clotrimazole may be the most potent topical
agent in this class of antifungals but is used as a
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topical agent only because of its gastrointestinal
and neurological toxicity (Odds, 1988).
2. Miconazole
Miconazole is used mainly for topical treat-
ment of candidosis. It is available for parenteral
use against systemic mycoses, but the injection
contains polyethoxylate castor oil, which may
provoke allergic reactions (Bodey, 1992).
3. Ketoconazole
Ketoconazole was the first of the imidazole
agents shown to be capable of achieving thera-
peutic blood levels when given orally. This led to
the drug being used in the treatment ofCMC and
candidosis in immunocompromised patients, but
adverse effects, including nausea, rashes, pruritus,
and hepatotoxicity, have restricted its use (Brass
etal., 1982).
4. Fluconazole
Fluconazole is a recently introduced bis-
triazole antifungal that acts by inhibiting fungal
ergosterol production essential in cell wall forma-
tion (Bammer et al., 1990). Fluconazole inhibits
the cytochrome c-dependent demethylation step
in the formation of ergosterol in the cell mem-
brane. Fluconazole has little affinity for mamma-
lian cytochromes, which is thought to explain its
apparently low toxicity (Hay, 1990a, 1990b).
Adhesion of Candida to epithelial cells, widely
recognized as the essential step in the process of
candidal colonization and subsequent infection
(Kennedy, 1988) is also significantly inhibited by
fluconazole (Darwazeh et al., 1991). Because
fluconazole is secreted in saliva in high concen-
tration, it is tempting to speculate that fluconazole
may interfere with the synthesis or structure of
Candida receptors on buccal epithelial cells (Far-
row, 1987).
Oral absorption of fluconazole is rapid and
nearly complete within 2 h (Washton, 1989). In-
travenous preparations are available for patients
who cannot take medication by mouth. Flucon-
azole appears to undergo relatively little metabo-
lism in the body, elimination being predominantly
renal (Brammer et al., 1990; Hay, 1990). With
normal renal function, the serum half-life is ap-
proximately 30 h. The concentration of drug in
the CSF is estimated to be between 50 to 90%
plasma concentration. All this suggests that
fluconazole is best given once daily and will pen-
etrate into CSF and urine in high concentration
(Humphrey et al., 1985).
Oral fluconazole has generally been well tol-
erated and, with usual doses, does not appear to
suppress the synthesis of corticosteroid hormones.
Elevated plasma concentration of tolbutamide,
phenytoin, and warfarin have been observed after
fluconazole administration, but without signifi-
cant effects (Breckenridge, 1992). Although seri-
ous cutaneous reactions and hepatitis have
occurred in a few patients receiving fluconazole,
these reactions appear to be infrequent and may
not be related to the fluconazole at all (Galgiani,
1990), although in a study by Franklin et al. (1990),
jaundice and abnormal liver function tests were
seen in some patients treated with fluconazole for
HIV-related oral candidal infection. Wells and
Lever (1992) reported a patient with AIDS-re-
lated oropharyngeal candidosis treated with
fluconazole who developed a dose-related liver
dysfunction.
In patients with chronic atrophic oral
candidosis, fluconazole is effective, particularly
when administered concurrently with an oral an-
tiseptic such as chlorhexidine (Hay, 1990b). In
patients with chronic mucocutaneous candidosis
in whom relapses after initial remission are ex-
pected, fluconazole in a dose of 50 mg produced
beneficial clinical and mycological responses in a
mean period of 10 d (Hay, 1990b).
The efficacy and toxicity offluconazole 50 mg
daily was compared with ketoconazole 200 mg
daily in a randomized prospective, double-blind
evaluation of patients with either AIDS or AIDS-
related complex. Infection was eradicated in all
patients treated with fluconazole, but in only 75%
of the patients who were given ketoconazole
(de Wit et al., 1989). It would seem that the re-
gime of 50 mg per day (single dose therapy) of
fluconazole for a period of 2 to 3 weeks may be
adequate to prevent or suppress candidosis in HIV-
infected patients. Indeed, 50 mg per day is the
dose recommended by the drug manufacturers for
the treatment of oral candidosis. Nevertheless,
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either maintenance therapy or intermittent therapy
with fluconazole is essential to prevent relapse
after cessation of treatment (Lewis et al., 1991).
AIDS patients treated with fluconazole
200 mg/d orally for approximately 3 weeks had
recurrence of oral and pharyngeal candidosis af-
ter the therapy was stopped. When the fluconazole
therapy was started again at the same dosage as
before, the patients had an incomplete response
(Lucatorto et al., 1991).
Patients undergoing therapy for metastatic
malignancy were randomly assigned to receive
fluconazole or placebo as antifungal prophylaxis.
Oropharyngeal candidosis developed in only 2%
of patients receiving fluconazole but in 28% of
patients receiving placebo. The favorable results
from this study indicate that fluconazole should
be evaluated as antifungal prophylaxis in patients
at greatest risk of developing serious fungal infec-
tions, such as transplant patients or those receiv-
ing chemotherapy for malignant diseases (Bodey
et al., 1990).
AIDS, and when treating infections at critical
sites, such as candidal meningitis and failures to
respond to triazoles such as fluconazole (Siegman-
Igra and Raban, 1992). None of the azoles are
entirely benign and they are expensive. Hepato-
toxicity may be common to all of them, and the
potential for endocrine toxicities exists, particu-
larly at high doses. Furthermore, as with any new
agent, novel toxicities may yet be discovered
(Graybill, 1989).
The introduction of any new antimicrobial is
almost always associated with the emergence of
resistant flora (Ayliffe, 1979). As far as triazoles
and Candida species are concerned, there are dis-
concerting reports that indicate that some yeasts
may have either developed or are developing re-
sistance (Evans et al., 1991; Smith et al., 1991 a;
Johnson et al., 1993).
The development of cross-resistance of
C. albicans to different imidazoles during treat-
ment with a single azole derivative has been de-
scribed (Holt and Azmi, 1978; Johnson et al.,
1984).
5. Itraconazole
This is an orally active bis-triazole, similar to
fluconazole, which inhibits ergosterol biosynthe-
sis in the fungal cell. It has a long half-life and
fewer side effects than ketoconazole but is expen-
sive (Jansen et al., 1991) and is eliminated
hepatically. Its use is contraindicated in liver dis-
ease. It is available in 50 and 100 mg capsules and
10 mg/ml oral solution. For a period of 2 weeks
100 to 200 mg/d gives good clinical and labora-
tory results compared with ketoconazole and
clotrimazole (Smith et al., 1991b; Blatchford,
1990).
The availability of an oral solution may offer
advantages over capsules because it will be easier
to swallow for patients with oral candidosis and
for administration by nasogastric tube (Blatchford,
1990).
6. Drawbacks of the Azoles
All the azoles (i.e., the imidazoles and
triazoles) are fungistatic, not fungicidal. This is
an important consideration when treating the
chronically immunosuppressed, such as those with
C. DNA Analogues
1. Flucytosine (5-Fluorocytosine)
This DNA analogue, which interferes with
nucleic acid synthesis of the yeast cells, may be
useful as oral therapy for systemic fungal infec-
tions in a dose of 50 to 150 mg/kg/d in divided
doses four times daily. Toxicity is due to meta-
bolic effects on rapidly dividing host cells such as
bone marrow cells. Other side effects are nausea,
vomiting, and hepatic dysfunction (Epstein, 1990).
XiII. CONDLUDING REMARKS
Although considerable progress has been made
in the understanding of Candida and oral
candidosis during the last few decades, much re-
mains to be done. The precise nature of determi-
nants of virulence of Candida, and the response
of host tissues to them, are still unclear, although
our knowledge on these and other aspects of
Candida pathogenicity has advanced consider-
ably due to recent applications of molecular bio-
logical techniques to investigate phenomena such
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as phenotypic switching. The increasing preva-
lence of oral Candida infections in HIV-infected
patients and the emergence of antifungal resis-
tance to the newer azoles has in addition renewed
the vigor and impetus of Candida research. Be-
cause of a combination of recent knowledge and
increasingly sophisticated technology, the future
for Candida research will doubtless be fruitful,
exciting, and highly rewarding.
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